Approval · Notice of Compliance 37904 · 2026
REMDANTRY: Notice of Compliance 37904
Issued July 15, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37904
- Date
- July 15, 2026
- Company
- Celltrion Inc.Incheon, --, Korea, Republic Of
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site
- Canadian reference product
- REMICADE
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REMDANTRY | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL